Determinants of the disparate antitumor effects of (6R)5,10-dideaza-5,6,7,8- tetrahydrofolate and methotrexate toward methotrexate resistant CCRF-CEM cells, characterized by severely impaired antifolate membrane transport.
Matherly
L H
LH
Development Therapeutics Program, Michigan Cancer Foundation, Detroit 48201.
Angeles
S M
SM
D000970:Antineoplastic Agents / Q000633:toxicity*; D002352:Carrier Proteins / Q000378:metabolism*; D002460:Cell Line; D004351:Drug Resistance; D058973:Folate Receptors, GPI-Anchored; D005493:Folic Acid Antagonists / Q000378:metabolism* / Q000633:toxicity*; D006801:Humans; D007700:Kinetics; D008727:Methotrexate / Q000378:metabolism / Q000633:toxicity*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma; D011956:Receptors, Cell Surface / Q000378:metabolism*; D013763:Tetrahydrofolates / Q000378:metabolism / Q000633:toxicity*; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D002352:Carrier Proteins; D058973:Folate Receptors, GPI-Anchored; D005493:Folic Acid Antagonists; D011956:Receptors, Cell Surface; D013763:Tetrahydrofolates; C045894:lometrexol; D008727:Methotrexate